Concepedia

Publication | Open Access

Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study

DOIFull Paper Access

103

Citations

14

References

2015

Year

Peter Johnson, Ruth Challis, Ferdousi Chowdhury, Yifang Gao, Melanie Harvey, T. Geldart, Paul Kerr, H.T. Claude Chan, Anna R. Smith, Neil Steven,
Clinical Cancer Research

Abstract

ChiLob7/4 can activate B and NK cells at doses that can be administered safely, and should be tested in combination with other antibodies and chemotherapy agents.

References

YearCitations

Page 1